VEGFA and age-related macular degeneration: However, studies conducted among patients with age-related macular degeneration (AMD) have shown that VMI pathologies strongly impact the efficacy of intravitreal anti-VEGF (vascular endothelial growth factor) therapy.6,7 Consequently, Munk et al.3 examined the effects of VMI pathology in the treatment of uveitis-related macular edema and demonstrated a larger and faster reduction in central retinal thickness in the PVD group as compared to the group with VMA but no PVD; however, they did not observe significant differences in visual acuity improvement or retinal volume.